Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Anal Canal Carcinoma 1

Interventions

Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Radiotherapy 3Mitomycin 3Fluorouracil 3Biopsy 3fludarabine phosphate 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Sigmoidoscopy 2Proctoscopy 2Ipilimumab 2Interleukin-12 Subunit p35 2Erlotinib Hydrochloride 2Cyclophosphamide 2Colonoscopy 2CTLA-4 Antigen 2tipifarnib 1tempol 1oncogene protein E7, Human papillomavirus type 16 1dehydroftorafur 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Serotonin Plasma Membrane Transport Proteins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Anus Neoplasms × Proctoscopy × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡